share_log

Valneva For 2024 Expects Total Revenues Of €170M-€190M And R&D Investments Between €60M-€75M

Benzinga ·  May 7 01:47

2024 financial guidance confirmed

  • Expected total revenues between €170 million and €190 million, including:
    • €160 million to €180 million of sales driven by growth of Valneva's proprietary products
  • Expected R&D investments between €60 million and €75 million, mostly dedicated to ongoing chikungunya development activities, the Zika trial and advancement of pre-clinical programs
  • Expected Other income between €100 million and €110 million, reflecting €95 million in proceeds from the PRV sale
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment